SAFINAZ MOSTAFA: Open Payments
NPI 1386027696 · BUFORD, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$675 in 36 payments from 9 companies in 2025. Trend: 2023 $540 · 2024 $606 · 2025 $675
Food & beverage: $675
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 8 | $165 |
| Otsuka America Pharmaceutical, Inc. | 8 | $149 |
| Neurocrine BioSciences, Inc. | 5 | $107 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $103 |
| ABBVIE INC. | 4 | $67 |
| Axsome Therapeutics, Inc. | 2 | $30 |
| Lundbeck LLC | 1 | $21 |
| Janssen Pharmaceuticals, Inc | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
Products named: COBENFY, INGREZZA, CAPLYTA, REXULTI, VRAYLAR, ABILIFY ASIMTUFII, ABILIFY MAINTENA, Auvelity.
Industry payments across GA — which companies pay providers there.
